152 related articles for article (PubMed ID: 17576064)
21. Synthesis and biological evaluation of thiophene and benzo[b]thiophene analogs of combretastatin A-4 and isocombretastatin A-4: A comparison between the linkage positions of the 3,4,5-trimethoxystyrene unit.
Do CV; Faouzi A; Barette C; Farce A; Fauvarque MO; Colomb E; Catry L; Berthier-Vergnes O; Haftek M; Barret R; Lomberget T
Bioorg Med Chem Lett; 2016 Jan; 26(1):174-80. PubMed ID: 26602281
[TBL] [Abstract][Full Text] [Related]
22. Aroyl-pyrrolyl hydroxyamides: influence of pyrrole C4-phenylacetyl substitution on histone deacetylase inhibition.
Mai A; Massa S; Valente S; Simeoni S; Ragno R; Bottoni P; Scatena R; Brosch G
ChemMedChem; 2006 Feb; 1(2):225-37. PubMed ID: 16892355
[TBL] [Abstract][Full Text] [Related]
23. Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization.
Kattar SD; Surdi LM; Zabierek A; Methot JL; Middleton RE; Hughes B; Szewczak AA; Dahlberg WK; Kral AM; Ozerova N; Fleming JC; Wang H; Secrist P; Harsch A; Hamill JE; Cruz JC; Kenific CM; Chenard M; Miller TA; Berk SC; Tempest P
Bioorg Med Chem Lett; 2009 Feb; 19(4):1168-72. PubMed ID: 19138845
[TBL] [Abstract][Full Text] [Related]
24. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
25. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs).
Schäfer S; Saunders L; Eliseeva E; Velena A; Jung M; Schwienhorst A; Strasser A; Dickmanns A; Ficner R; Schlimme S; Sippl W; Verdin E; Jung M
Bioorg Med Chem; 2008 Feb; 16(4):2011-33. PubMed ID: 18054239
[TBL] [Abstract][Full Text] [Related]
26. Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Price S; Bordogna W; Braganza R; Bull RJ; Dyke HJ; Gardan S; Gill M; Harris NV; Heald RA; van den Heuvel M; Lockey PM; Lloyd J; Molina AG; Roach AG; Roussel F; Sutton JM; White AB
Bioorg Med Chem Lett; 2007 Jan; 17(2):363-9. PubMed ID: 17107790
[TBL] [Abstract][Full Text] [Related]
27. Discovery of thieno[2,3-c]pyridines as potent COT inhibitors.
George D; Friedman M; Allen H; Argiriadi M; Barberis C; Bischoff A; Clabbers A; Cusack K; Dixon R; Fix-Stenzel S; Gordon T; Janssen B; Jia Y; Moskey M; Quinn C; Salmeron JA; Wishart N; Woller K; Yu Z
Bioorg Med Chem Lett; 2008 Sep; 18(18):4952-5. PubMed ID: 18755587
[TBL] [Abstract][Full Text] [Related]
28. Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors.
Kim HM; Hong SH; Kim MS; Lee CW; Kang JS; Lee K; Park SK; Han JW; Lee HY; Choi Y; Kwon HJ; Han G
Bioorg Med Chem Lett; 2007 Nov; 17(22):6234-8. PubMed ID: 17904843
[TBL] [Abstract][Full Text] [Related]
29. Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
Andrianov V; Gailite V; Lola D; Loza E; Semenikhina V; Kalvinsh I; Finn P; Petersen KD; Ritchie JW; Khan N; Tumber A; Collins LS; Vadlamudi SM; Björkling F; Sehested M
Eur J Med Chem; 2009 Mar; 44(3):1067-85. PubMed ID: 18672316
[TBL] [Abstract][Full Text] [Related]
30. Probing acid replacements of thiophene PTP1B inhibitors.
Wan ZK; Follows B; Kirincich S; Wilson D; Binnun E; Xu W; Joseph-McCarthy D; Wu J; Smith M; Zhang YL; Tam M; Erbe D; Tam S; Saiah E; Lee J
Bioorg Med Chem Lett; 2007 May; 17(10):2913-20. PubMed ID: 17336064
[TBL] [Abstract][Full Text] [Related]
31. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation.
Tang H; Wang XS; Huang XP; Roth BL; Butler KV; Kozikowski AP; Jung M; Tropsha A
J Chem Inf Model; 2009 Feb; 49(2):461-76. PubMed ID: 19182860
[TBL] [Abstract][Full Text] [Related]
32. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
[TBL] [Abstract][Full Text] [Related]
33. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate.
Sekhavat A; Sun JM; Davie JR
Biochem Cell Biol; 2007 Dec; 85(6):751-8. PubMed ID: 18059533
[TBL] [Abstract][Full Text] [Related]
34. Benzo[b]thiophene-2-carboxamides and benzo[b]furan-2-carboxamides are potent antagonists of the human H3-receptor.
Peschke B; Bak S; Hohlweg R; Nielsen R; Viuff D; Rimvall K
Bioorg Med Chem Lett; 2006 Jun; 16(12):3162-5. PubMed ID: 16616493
[TBL] [Abstract][Full Text] [Related]
35. Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles.
Dehmel F; Weinbrenner S; Julius H; Ciossek T; Maier T; Stengel T; Fettis K; Burkhardt C; Wieland H; Beckers T
J Med Chem; 2008 Jul; 51(13):3985-4001. PubMed ID: 18558669
[TBL] [Abstract][Full Text] [Related]
36. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
37. The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor.
Yurek-George A; Cecil AR; Mo AH; Wen S; Rogers H; Habens F; Maeda S; Yoshida M; Packham G; Ganesan A
J Med Chem; 2007 Nov; 50(23):5720-6. PubMed ID: 17958342
[TBL] [Abstract][Full Text] [Related]
38. Antifungal activity of synthetic di(hetero)arylamines based on the benzo[b]thiophene moiety.
Pinto E; Queiroz MJ; Vale-Silva LA; Oliveira JF; Begouin A; Begouin JM; Kirsch G
Bioorg Med Chem; 2008 Sep; 16(17):8172-7. PubMed ID: 18678498
[TBL] [Abstract][Full Text] [Related]
39. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
Moradei OM; Mallais TC; Frechette S; Paquin I; Tessier PE; Leit SM; Fournel M; Bonfils C; Trachy-Bourget MC; Liu J; Yan TP; Lu AH; Rahil J; Wang J; Lefebvre S; Li Z; Vaisburg AF; Besterman JM
J Med Chem; 2007 Nov; 50(23):5543-6. PubMed ID: 17941625
[TBL] [Abstract][Full Text] [Related]
40. Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.
Bora-Tatar G; Dayangaç-Erden D; Demir AS; Dalkara S; Yelekçi K; Erdem-Yurter H
Bioorg Med Chem; 2009 Jul; 17(14):5219-28. PubMed ID: 19520580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
